Clinical trial on ibandronate in patients with tumor-associated hypercalcemia
Wang, T.; Song, S.-t.; Jiang, Z.-f.; Bian, S.-g.; Wang, Y.-j.; Li, L.-q.; Zhu, J.
Zhonghua Zhong Liu Za Zhi 26(12): 739-741
2004
ISSN/ISBN: 0253-3766 PMID: 15733393 Document Number: 580312
Ibandronate, a third generation bisphosphonate, inhibits bone resorption in human and animal studies. This study is to evaluate the efficacy and safety of ibandronate as a single agent in patients with tumor-associated hypercalcemia. An open, multicenter, non-controlled clinical trial was conducted in 22 patients. The patients received 2 mg ibandronate intravenously if the corrected calcium was less than 3.0 mmol/L but more than 2.7 mmol/L; they received 4 mg ibandronate iv if corrected calcium was more than 3.0 mmol/L. There was 100% efficacy in these two dose groups but the calcium correcting effect was more pronounced in the 4-mg dose group than the 2-mg dose group. The most common adverse reactions were fever and skin itching with an incidence of 4.5%. Ibandronate is active in patients with tumor-associated hypercalcemia and the adverse effects are well tolerated.